Note 15 - Condensed Consolidating Financial Information Of Guarantor Subsidiaries (Detail) - Condensed Consolidating Cash Flow Information (USD $) In Thousands, unless otherwise specified	3 Months Ended	6 Months Ended	9 Months Ended
	Aug. 19, 2011	Feb. 29, 2012	Feb. 28, 2011	May 31, 2011	May 31, 2010
Net cash provided by (used in) operating activities	$ 25,588	$ (4,662)	$ 73,666
Net cash used in investing activities	(2,265)	(1,942,673)	(5,533)
Net cash provided by ( used in) financing activities	66	1,653,627	430
Effect of exchange rate changes on cash and cash equivalents	(3,029)	(1,250)	3,466
Increase (decrease) in cash and cash equivalents	20,360	(294,958)	72,029
Cash and cash equivalents	322,963	28,005	274,678	302,603	202,649
Ending Balance [Member] | Total [Member] | Predecessor [Member]
Cash and cash equivalents	322,963		274,678
Ending Balance [Member] | Total [Member] | Successor [Member]
Cash and cash equivalents		28,005
Ending Balance [Member] | Non-Guarantors [Member] | Predecessor [Member]
Cash and cash equivalents	8,748		46,960
Ending Balance [Member] | Non-Guarantors [Member] | Successor [Member]
Cash and cash equivalents		13,559
Ending Balance [Member] | Guarantor [Member] | Predecessor [Member]
Cash and cash equivalents	(89)		(78)
Ending Balance [Member] | Guarantor [Member] | Successor [Member]
Cash and cash equivalents		(144)
Ending Balance [Member] | Immucor Inc [Member] | Predecessor [Member]
Cash and cash equivalents	314,304		227,796
Ending Balance [Member] | Immucor Inc [Member] | Successor [Member]
Cash and cash equivalents		14,590
Beginning Balance [Member] | Total [Member] | Predecessor [Member]
Cash and cash equivalents	302,603		202,649
Beginning Balance [Member] | Total [Member] | Successor [Member]
Cash and cash equivalents		322,963
Beginning Balance [Member] | Non-Guarantors [Member] | Predecessor [Member]
Cash and cash equivalents	52,297		31,783
Beginning Balance [Member] | Non-Guarantors [Member] | Successor [Member]
Cash and cash equivalents		8,748
Beginning Balance [Member] | Guarantor [Member] | Predecessor [Member]
Cash and cash equivalents	(80)		(278)
Beginning Balance [Member] | Guarantor [Member] | Successor [Member]
Cash and cash equivalents		(89)
Beginning Balance [Member] | Immucor Inc [Member] | Predecessor [Member]
Cash and cash equivalents	250,386		171,144
Beginning Balance [Member] | Immucor Inc [Member] | Successor [Member]
Cash and cash equivalents		314,304
Total [Member] | Predecessor [Member]
Net cash provided by (used in) operating activities	25,588		73,666
Net cash used in investing activities	(2,265)		(5,533)
Net cash provided by ( used in) financing activities	66		430
Effect of exchange rate changes on cash and cash equivalents	(3,029)		3,466
Increase (decrease) in cash and cash equivalents	20,360		72,029
Cash and cash equivalents				302,603
Total [Member] | Successor [Member]
Net cash provided by (used in) operating activities		(4,662)
Net cash used in investing activities		(1,942,673)
Net cash provided by ( used in) financing activities		1,653,627
Effect of exchange rate changes on cash and cash equivalents		(1,250)
Increase (decrease) in cash and cash equivalents		(294,958)
Cash and cash equivalents		28,005
Corporate Elimination [Member] | Predecessor [Member]
Net cash provided by (used in) operating activities	(24,978)		767
Net cash provided by ( used in) financing activities	25,083
Effect of exchange rate changes on cash and cash equivalents	(105)		(767)
Cash and cash equivalents				(80)
Corporate Elimination [Member] | Successor [Member]
Net cash provided by (used in) operating activities		(9,978)
Net cash provided by ( used in) financing activities		10,752
Effect of exchange rate changes on cash and cash equivalents		(774)
Cash and cash equivalents		(144)
Non-Guarantors [Member] | Predecessor [Member]
Net cash provided by (used in) operating activities	(13,821)		12,499
Net cash used in investing activities	(1,719)		(1,555)
Net cash provided by ( used in) financing activities	(25,085)
Effect of exchange rate changes on cash and cash equivalents	(2,924)		4,233
Increase (decrease) in cash and cash equivalents	(43,549)		15,177
Cash and cash equivalents				52,297
Non-Guarantors [Member] | Successor [Member]
Net cash provided by (used in) operating activities		16,680
Net cash used in investing activities		(640)
Net cash provided by ( used in) financing activities		(10,753)
Effect of exchange rate changes on cash and cash equivalents		(476)
Increase (decrease) in cash and cash equivalents		4,811
Cash and cash equivalents		13,559
Guarantor [Member] | Predecessor [Member]
Net cash provided by (used in) operating activities	144		480
Net cash used in investing activities	(153)		(280)
Increase (decrease) in cash and cash equivalents	(9)		200
Guarantor [Member] | Successor [Member]
Net cash provided by (used in) operating activities		310
Net cash used in investing activities		(365)
Increase (decrease) in cash and cash equivalents		(55)
Immucor Inc [Member] | Predecessor [Member]
Net cash provided by (used in) operating activities	64,243		59,920
Net cash used in investing activities	(393)		(3,698)
Net cash provided by ( used in) financing activities	68		430
Increase (decrease) in cash and cash equivalents	63,918		56,652
Cash and cash equivalents				250,386
Immucor Inc [Member] | Successor [Member]
Net cash provided by (used in) operating activities		(11,674)
Net cash used in investing activities		(1,941,668)
Net cash provided by ( used in) financing activities		1,653,628
Increase (decrease) in cash and cash equivalents		(299,714)
Cash and cash equivalents		$ 14,590